Literature DB >> 35900688

Fear of Cancer Recurrence in peritoneal malignancy patients following treatment: a cross-sectional study.

Rayan Taher1, Norman John Carr2, Nancy Vanderpuye2, Sophia Stanford2.   

Abstract

PURPOSE: To assess Fear of Cancer Recurrence (FCR)-its prevalence, trajectory, and relationship to several demographic and clinical characteristics, and quality of life-in a sample of peritoneal malignancy survivors, up to 5 years post-surgery.
METHODS: The Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) and 36-Item Short-Form Health Survey (SF-36) were used to collect cross-sectional data from peritoneal malignancy survivors to assess their Fear of Cancer Recurrence and quality of life respectively as well as other demographic and clinical data.
RESULTS: The results show that more than two-thirds of the participants (N = 301) experience severe/clinical FCR. FCR is relatively stable over time. Younger patients who are struggling with anxiety or depression or receiving professional mental health support at the time of the surgery are at a higher risk of FCR. FCR is associated with a worse quality of life.
CONCLUSIONS: Peritoneal malignancy survivors are at a high risk of FCR, and it compromises their psychological, mental, and social well-being (quality of life). IMPLICATIONS FOR CANCER SURVIVORS: Raise awareness about the high risk of FCR in this population and the demographic and clinical factors that are associated with it. Encourage peritoneal malignancy services and health professionals to address FCR in this population by normalizing it and providing support for those struggling with it.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CRS and HIPEC; FCR; Fear of Cancer Recurrence; Peritoneal malignancy; Quality of life; Surgery

Year:  2022        PMID: 35900688     DOI: 10.1007/s11764-022-01238-4

Source DB:  PubMed          Journal:  J Cancer Surviv        ISSN: 1932-2259            Impact factor:   4.062


  4 in total

1.  Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for management of peritoneal metastases.

Authors:  Yue Zhu; Nader Hanna; Cherif Boutros; H Richard Alexander
Journal:  J Gastrointest Oncol       Date:  2013-03

2.  Outcomes of home parenteral nutrition in 34 patients with intestinal failure from recurrent or progressive peritoneal malignancy of gastro-intestinal tract origin.

Authors:  David Swain; Gemma Mason; Allison Yates; Sara Burke; Tom Cecil; Faheez Mohamed; Sanjeev Dayal; Alexios Tzivanakis; Brendan Moran
Journal:  Eur J Clin Nutr       Date:  2020-11-21       Impact factor: 4.016

3.  Screening and comorbidity of clinical levels of fear of cancer recurrence.

Authors:  Sébastien Simard; Josée Savard
Journal:  J Cancer Surviv       Date:  2015-01-21       Impact factor: 4.442

4.  The cost of cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of peritoneal malignancy in one Greek institute.

Authors:  A A Tentes; N Pallas; O Korakianitis; C Mavroudis; A Spiridonidou; G Zorbas; S Popidis; N Papadoniou; V Darladima; A Smyrnis; C Siopis
Journal:  J BUON       Date:  2012 Oct-Dec       Impact factor: 2.533

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.